AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:

Claims 1-20. (Canceled)

1 ~~21~~. (Previously Presented) An isolated polypeptide consisting of:

(i) a sequence consisting of the amino acid sequence KNIRRRVYDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1); or

(ii) a sequence consisting of the amino acid sequence KNIRRRVYDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1) and attached to 1 to 5 amino acid residues at the N- or C-terminus of SEQ ID NO:1, where the presence of said 1 to 5 amino acid residues has no significant effect on the function of the polypeptide.

2 ~~22~~. (Currently Amended) An isolated polypeptide consisting of:

(i) the amino acid sequence of SEQ ID NO:2; or

(ii) the amino acid sequence of SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 or SEQ ID NO:6; or

(iii) the amino acid sequence of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:6 joined to 1 to 5 amino acid residues at at least one of the N- or C-terminus of said SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:6, where the

presence of said 1 to 5 amino acid residues has no significant effect on the function of the polypeptide, or

(iv) the amino acid sequence of SEQ ID NO:5 joined to 1 to 5 amino acid residues at the C-terminus of said SEQ ID NO:5, where the presence of said 1 to 5 amino acid residues has no significant effect on the function of the polypeptide,

which polypeptide is capable of antagonising the heterodimerisation of a DP protein with an E2F protein.

~~a fragment of a sequence consisting of the amino acid sequence KNIRRRVYDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1), and from 1 to 5 amino acid residues joined to at least one of the N- or C-terminus of the fragment, where the presence of the 1 to 5 amino acid residues has no significant effect on the function of the polypeptide;~~

~~which polypeptide is capable of antagonising the heterodimerisation of a DP protein with an E2F protein.~~

Claims 23-24. (Canceled)

3 ~~25.~~ (Previously Presented) An isolated variant of a polypeptide consisting of:

(i) a sequence consisting of the amino acid sequence KNIRRRVYDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1), or

(ii) a sequence consisting of the amino acid sequence KNIRRRVYDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1) attached to 1 to 5 amino acid residues at the N- or C-terminus of SEQ ID NO:1, where the presence of said 1 to 5 amino acid residues has no significant effect on the function of the polypeptide;

said variant differing from the polypeptide by the presence of from 1 to 5 amino acid substitutions in the sequence of said polypeptide, said variant being capable of antagonising the heterodimerisation of a DP protein with an E2F protein.

4 26. (Previously Presented) The variant according to claim 25 3 wherein the substitutions include substitutions selected from one or more residues corresponding to residues 167, 169, 171 and 175 of DP-1.

5 27. (Previously Presented) An isolated polypeptide consisting of an amino acid sequence (i) attached to an amino acid sequence (ii) wherein said amino acid sequence (ii) is attached to the N- or C- terminus of said amino acid sequence (i),

said amino acid sequence (i) consisting of an amino acid sequence selected from the group consisting of:

(a) KNIRRRVYDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1),

(b) NVLMAMNII (SEQ ID NO:2),

(c) RRRVYDALNVLMAMNIISK (SEQ ID NO:3),

(d) NVLMAMNIISKEKKEIKWIG (SEQ ID NO:4),

(e) RVYDALNVLMAMNIIS (SEQ ID NO:5),

(f) YDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:6), and

(g) ALNVLMA (SEQ ID NO:7); and

said amino acid sequence (ii) consisting of a sequence of amino acids not naturally contiguous to said amino sequence (i).

6 ~~28~~. (Previously Presented) A polypeptide according to claim 27 wherein the amino acid sequence (ii) is a membrane translocation sequence.

7 ~~29~~. (Previously Presented) A polypeptide according to claim 28 wherein the membrane translocation sequence is a membrane translocation sequence of the Drosophila melanogaster antennapedia protein.

8 ~~30~~. (Previously Presented) A composition comprising a polypeptide according to any one of claims ~~21 to 29~~ together with a pharmaceutically acceptable diluent or carrier. ~~21, 26, or 25 to 29~~ 1 2 3 7

MM 9-7-06

9 ~~31~~. (Previously Presented) A composition according to claim ~~30~~ 8 which further comprises a cytostatic or cytotoxic agent.

10 ~~32~~. (Previously Presented) A composition formulation comprising a polypeptide of SEQ ID NO:1 in the form of an orally, topically or parenteraly administrable form.

(d) NVLMAMNIISKEKKEIKWIG (SEQ ID NO:4),

~~(e) RVYDALNVLMAMNIIS (SEQ ID NO:5),~~

(f) YDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:6), and

(g) ALNVLMA (SEQ ID NO:7); and

said amino acid sequence (II) consisting of a sequence of amino acids not naturally contiguous to said amino sequence (i).

6 ~~28~~. (Previously Presented) A polypeptide according to claim 27 wherein the amino acid sequence (ii) is a membrane translocation sequence.

7 ~~29~~. (Previously Presented) A polypeptide according to claim 28 wherein the membrane translocation sequence is a membrane translocation sequence of the Drosophila melanogaster antennapedia protein.

8 ~~30~~. (Previously Presented) A composition comprising a polypeptide according to any one of claims 21 to 29 together with a pharmaceutically acceptable diluent or carrier.

9 ~~31~~. (Previously Presented) A composition according to claim 30 which further comprises a cytostatic or cytotoxic agent.

10 ~~32~~. (Previously Presented) A composition formulation comprising a polypeptide of SEQ ID NO:1 in the form of an orally, topically or parenteraly administrable form.

Claims 33-35. (Canceled)

36. (Previously Presented) An isolated product comprising a polypeptide consisting of:

(i) a sequence consisting of the amino acid sequence KNIRRRVYDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1), or

(ii) a sequence consisting of the amino acid sequence KNIRRRVYDALNVLMAMNIISKEKKEIKWIGLPTNSA (SEQ ID NO:1) attached to 1 to 5 amino acid residues at the N- or C-terminus of SEQ ID NO:1, where the presence of the 1 to 5 amino acid residues has no significant effect on the function of the polypeptide;

and a cytostatic or cytotoxic agent as a combined preparation.

Claim 37. (Canceled)